|
Originally published In Press as doi:10.1074/jbc.M702170200 on October 17, 2007
J. Biol. Chem., Vol. 282, Issue 52, 37378-37388, December 28, 2007
Phorbol Ester-induced Shedding of the Prostate Cancer Marker Transmembrane Protein with Epidermal Growth Factor and Two Follistatin Motifs 2 Is Mediated by the Disintegrin and Metalloproteinase-17*
Nazim Ali and
Vera Knaüper1
From the
Metalloproteinase Research Group, Department of Biology, University of York, Heslington, York YO10 5YW, United Kingdom
The transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) is expressed in prostate and brain and shed from the cell surface in a metalloproteinase-dependent fashion. Neither the sheddase(s) responsible for TMEFF2 shedding nor the physiological significance or activity of the soluble TMEFF2 ectodomain (TMEFF2-ECD) has been identified. In the present study we present new evidence that a disintegrin and metalloproteinase-17 (ADAM17) is responsible for phorbol 12-myristate 13-acetate-induced release of TMEFF2-ECD using small interfering RNA to ablate ADAM17 expression or by inhibiting enzymatic activity. A single well shedding assay monitoring the release of alkaline phosphatase-tagged TMEFF2-ECD into medium and the generation of 22- and 14-kDa C-terminal fragments in lysates were dependent on ADAM17 activity. A -secretase inhibitor prevented the formation of a 10-kDa fragment in cell lysates, thus establishing TMEFF2 as a novel substrate for regulated intramembrane proteolysis. We assigned proliferation-inducing activity to TMEFF2. Inhibition of TMEFF2 shedding using synthetic metalloproteinase inhibitors or small interfering RNA targeting TMEFF2 expression yielded a statistically significant reduction of cell proliferation in the lymph node-derived prostate cancer cells (LNCaPs) and a human embryonic kidney (HEK293) cell line overexpressing TMEFF2. The TMEFF2-ECD was able to induce ERK1/2 phosphorylation in an epidermal growth factor receptor (or ErbB1)-dependent manner in HEK293 cells. Our data suggest that TMEFF2 contributes to cell proliferation in an ADAM17-dependent autocrine fashion in cells expressing this protein.
Received for publication, March 13, 2007
, and in revised form, September 27, 2007.
* This study was supported by the Biotechnology and Biological Sciences Research Council and Smith & Nephew. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org) contains supplemental information and Fig. S1.
1 To whom correspondence should be addressed: Metalloproteinase Research Group, Matrix Biology and Tissue Repair Research Unit, Dental School, Cardiff University, Heath Park, Cardiff, Wales CF14 4XY, UK. Tel.: 44-029-2074-2595; Fax: 44-029-2074-4509; E-mail: KnauperV{at}cf.ac.uk.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. J. Duffy, E. McKiernan, N. O'Donovan, and P. M. McGowan
Role of ADAMs in Cancer Formation and Progression
Clin. Cancer Res.,
February 15, 2009;
15(4):
1140 - 1144.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|